Arcus biosciences presents early data from arc-6, a phase 1b/2 study evaluating etrumadenant-based combinations in metastatic castrate-resistant prostate cancer at the 2021 asco annual meeting

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced initial efficacy and safety data from one of the cohorts in arc-6, a randomized phase 1b/2 platform study, evaluating the novel combination of etrumadenant (dual adenosine a2a/a2b receptor antagonist) plus zimberelimab (anti-pd1 antibody) and docetaxel in people with taxane-naÏve mcrpc who progressed following trea
RCUS Ratings Summary
RCUS Quant Ranking